Entrectinib

INN name:	Entrectinib
Lab codes:	RXDX-101
Chemical name:	N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide
Molecular formula:	C31H34F2N6O2
Chemical Structure:
CAS Registry Number:	1108743-60-7
Originator:	Nerviano Medical Sciences
Developer:	Ignyta; Nerviano Medical Sciences
Class:	Antineoplastics
Mechanism of Action:	Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
WHO ATC code:	L01X-E (Protein kinase inhibitors)
EPhMRA code:	L1H (Protein Kinase Inhibitor Antineoplastics)
Clinical Trials: Indication                  Phase Status Locally Advanced Solid Tumors;   Metastatic Solid Tumors Phase 1 / Phase 2 Recruiting
Product Patent Expiry: For patent data contact us at drugpatentexpiry@gmail.com

Spebrutinib

INN name:	Spebrutinib
Lab codes:	AVL-292, CC-292
Chemical name:	N-[3-({5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl}amino)phenyl]prop-2-enamide
Molecular formula:	C22H22FN5O3
Chemical Structure:	Add caption
CAS Registry Number:	1202757-89-8
Originator:	Avila Therapeutics
Developer:	Celgene Corporation
Class:	Antineoplastic
Mechanism of Action:	Tyrosine kinase inhibitor
WHO ATC code:	L01X-E (Protein kinase inhibitors) M01A (Antiinflammatory and Antirheumatic Products, Non-steroids)
EPhMRA code:	L1H (Protein Kinase Inhibitor Antineoplastics) M1A (Anti-Rheumatics, Non-Steroidal)
Clinical Trials: Conditions Phases Interventions Status Rheumatoid Arthritis Phase 2 Alone Recruiting Lymphoma, Large B-Cell, Diffuse Phase 1 Combination Recruiting Relapsed/Refractory B-cell Lymphoma Phase 1 Combination Active, not recruiting Healthy Volunteers Phase 1 Combination Completed Leukemia Lymphocytic Chronic B-Cell Phase 1 Combination Active, not recruiting Leukemia Lymphocytic Chronic B-Cell Phase 1 Combination Active, not recruiting B Cell Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia Phase 1 Alone Completed
Recent activities on the drug:

Tazemetostat

INN name:	Tazemetostat
Lab codes:	E-7438, EPZ-6438
Chemical name:	N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(oxan-4-yl)amino]-4-methyl-4'-[(morpholin-4-yl)methyl][1,1'-biphenyl]-3-carboxamide
Molecular formula:	C34H44N4O4
Chemical Structure:
CAS Registry Number:	1403254-99-8
Originator:	Epizyme
Class:	Antineoplastic
Mechanism of Action:	EZH2 enzyme inhibitors
WHO ATC code:	L01X-X
EPhMRA code:	L1X9
Clinical Trials: Indication Phase Status Follicular Lymphoma Phase 2 Recruiting Diffuse Large B-cell Lymphoma Phase 2 Recruiting Advanced Solid Tumors Phase 1 Recruiting B-cell Lymphoma Phase 1 Recruiting

Abemaciclib

INN name:	abemaciclib
Lab codes:	LY-2835219
Chemical name:	N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine
Molecular formula:	C27H32F2N8
Chemical Structure:
CAS Registry Number:	1231929-97-7
Originator:	Eli Lilly
Class:	Antineoplastic
Mechanism of Action:	Cyclin-dependent kinase 4, 6 inhibitors
WHO ATC code:	L01X-E
EPhMRA code:	L1H
Clinical Trials:
Conditions Phases Interventions Status Breast Cancer Phase 3 Combination Recruiting Breast Neoplasms Phase 3 Combination Recruiting Non Small Cell Lung Cancer Phase 3 Combination Recruiting Breast Cancer|Brain Metastases Phase 2 Alone Recruiting Breast Cancer|Hormone Receptor Positive Tumor|Early-Stage Breast Carcinoma Phase 2 Combination Not yet recruiting Mantle Cell Lymphoma Phase 2 Alone Active, not recruiting Metastatic Breast Cancer Phase 2 Alone Active, not recruiting Non-Small Cell Lung Cancer Stage IV Phase 2 Combination Recruiting Advanced Cancer Phase 1 Combination Active, not recruiting Breast Neoplasms Phase 1 Combination Recruiting Carcinoma, Non-small Cell Lung Phase 1 Combination Recruiting Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis Phase 1 Combination Recruiting Hepatic Insufficiency|Healthy Phase 1 Alone Completed Neoplasm Metastasis|Lymphoma Phase 1 Alone Active, not recruiting Neoplasm|Neoplasm Metastasis Phase 1 Combination Active, not recruiting
Recent activities on the drug:

Infigratinib

INN name:	Infigratinib
Lab codes:	BGJ-398; NVP-BGJ398
Chemical name:	N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-{6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl}-N-methylurea
Molecular formula:	C26H31Cl2N7O3
Chemical Structure:	Add caption
CAS Registry Number:	872511-34-7
Originator:	Novartis
Class:	Antineoplastics
Mechanism of Action:	Tyrosine kinase inhibitor
WHO ATC code:	L01X-E
EPhMRA code:	L1H
Clinical Trials:
Conditions Phases Interventions Status Advanced Cholangiocarcinoma Phase 2 Alone Recruiting Melanoma Phase 2 Combination Active, not recruiting Melanoma Phase 2 Combination Recruiting Recurrent Glioblastoma or Other Glioma Subtypes Phase 2 Alone Recruiting Solid Tumor|Hematologic Malignancies Phase 2 Alone Recruiting Advanced Gastrointestinal Stromal Tumor (GIST) Phase 1|Phase 2 Combination Recruiting Advanced Solid Malignancies Phase 1 Alone Recruiting Advanced Solid Tumors,|Metastatic Solid Tumors Phase 1 Combination Recruiting Cancer of Cervix|Tumors Phase 1 Combination Withdrawn Tumor With Alterations of the FGF-R Phase 1 Alone Recruiting